DONALD E. BOBO JR - 28 Jan 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
28 Jan 2022
Transactions value $
-$877,233
Form type
4
Filing time
31 Jan 2022, 20:25:44 UTC
Previous filing
10 Dec 2021
Next filing
11 Feb 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Gift $0 +1,000 +1.8% $0 57,399 22 Dec 2021 Direct F1
transaction EW Common Stock Options Exercise $240,448 +11,050 +19% $21.76 68,449 28 Jan 2022 Direct F2
transaction EW Common Stock Sale -$49,117 -500 -0.73% $98.23 67,949 28 Jan 2022 Direct F2, F3
transaction EW Common Stock Sale -$69,678 -700 -1% $99.54 67,249 28 Jan 2022 Direct F2, F4
transaction EW Common Stock Sale -$274,657 -2,700 -4% $101.72 64,549 28 Jan 2022 Direct F2, F5
transaction EW Common Stock Sale -$313,172 -3,058 -4.7% $102.41 61,491 28 Jan 2022 Direct F2, F6
transaction EW Common Stock Sale -$411,054 -4,092 -6.7% $100.45 57,399 28 Jan 2022 Direct F2, F7
holding EW Common Stock 38,157 28 Jan 2022 401(k) F8
holding EW Common Stock 123,820 28 Jan 2022 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -11,050 -25% $0 33,150 28 Jan 2022 Common Stock 11,050 $21.76 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents an estate gift transferred on December 22, 2021.
F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 1, 2021.
F3 This transaction was executed in multiple trades at prices ranging from $97.730 to $98.360. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $99.070 to $100.000 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $101.340 to $102.190. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $102.340 to $102.655. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $100.090 to $100.970. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F8 Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.